共 504 条
[1]
Arrieta O(2013)Consenso nacional de diagnóstico y tratamiento del cáncer de pulmón de células no pequeñas Rev. Invest. Cli. 65 S5-S84
[2]
Guzmán-de Alba E(2011)Global cancer statistics CA Cancer J. Clin. 61 69-90
[3]
Alba-López LF(2008)Wood-smoke exposure as a response and survival predictor in erlotinib-treated non-small cell lung cancer patients: an open label phase II study J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 3 887-893
[4]
Acosta-Espinoza A(2004)Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis JAMA 292 470-484
[5]
Alatorre-Alexander J(2003)Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial) [corrected] J.Clin. Oncol. Off. J Am. Soc. Clin. Oncol. 21 2237-2246
[6]
Alexander-Meza JF(2005)The treatment of advanced non-small cell lung cancer Curr. Opin. Pulm. Med. 11 287-291
[7]
Allende-Pérez SR(2008)Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials J.Clin. Oncol. Off. J Am. Soc. Clin. Oncol. 26 4617-4625
[8]
Alvarado-Aguilar S(2003)Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial JAMA 290 2149-2158
[9]
Araujo-Navarrete ME(2005)Erlotinib in previously treated non-small-cell lung cancer New Engl. J. Med. 353 123-132
[10]
Argote-Greene LM(2005)Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 1527-1537